Welcome to Serenity

LDN (Low Dose Naltrexone) 40 capsules


Low Dose Naltrexone, 40 capsules. 4mg

STOP. No, really stop. Read this.

Do you want more medicine for your money? Of course you do.

Do you know nothing of Bitcoins, or simply cannot be bothered with the learning curve of buying and sending? It's likely

Do you want to pay by credit card? Probably.

Then, and heed this well.

Go to www.skrill.com (it is just like PayPal).

Sign up and register your credit card (takes less than 5 minutes).

Transfer the money to us.

You get all of the benefits of credit card fraud protection and ease of use, we get the cash.


We we give you 20% more medicine for your trouble.

A good deal.

If you are interested, forget this shopping cart and email us now at support@mod4all.com Mail us and we'll guide you through the process.

mail us at support@mod4all.com if you need to know more, or just want to chat. Mail us any time.

Naltrexone is drug developed initially to treat addiction to opiate-based drugs, such as heroin or morphine. It belongs to a class of medications called opiate antagonists.

Naltrexone delivered in lower doses – Low Dose Naltrexone (LDN) – has been used in the USA to treat the symptoms of autoimmune conditions, such as multiple sclerosis, since 1985, and more recently has been used in Europe and the UK.

The low dose method of taking naltrexone was devised and developed by the late Dr Bernard Bihari, from New York. Dr Bihari was qualified in Internal Medicine, Psychiatry and Neurology.

LDN is advocated as a treatment for the symptoms of many conditions including Crohn’s disease, fibromyalgia, Chronic Fatigue Syndrome and coeliac disease conditions with an autoimmune origin, or potential autoimmune origin.

How Naltrexone works

As an opiate antagonist, Naltrexone is thought to inhibit endorphins – the body’s natural painkiller. It is believed that by inhibiting endorphins, the body reacts by producing more. This increase in endorphins reduces pain and increases a sense of wellbeing.

Dr Bihari’s initial research showed that increased levels of endorphins stimulated the immune system and promoted an increase in a type of white blood cells – T-lymphocytes. Although not proven, it is believed people with autoimmune conditions have low levels of T-cells, so an increase in T-cells balances the immune system.

Many people with MS report significant improvements in their symptoms – particularly fatigue, pain, mood and spasm – after they start taking LDN.

Research into LDN

There have been many studies into the safety and effectiveness of LDN as a treatment for MS, and other conditions.

A pilot trial of 40 people with primary progressive MS conducted by Dr M Gironi found Naltrexone to be well-tolerated by the patients, who reported an improvement of their symptoms – especially in relation to spasticity.

The study was published in September 2008 in the Multiple Sclerosis Journal.

In 2011, Dr Rahn looked at experimental autoimmune encephalomyelitis (EAE) – an animal model for MS in mice – and the effect of LDN. Published in Brain Research, the study proved that after 60 days, the progression of EAE was halted in mice treated with LDN, and neurological deficits reversed.

Another 17-week randomised trial, where some people were given LDN, and some a placebo, looked into the effects of LDN in relation to quality of life. Ninety-six people were enrolled in the trial – some with relapsing-remitting MS and some with secondary progressive MS. This trial, conducted in 2010 by Dr N Sharafaddinzadeh published in the Multiple Sclerosis Journal, demonstrated the safety of LDN.

However, the results on LDN’s effect on quality of life (as measured by physical and mental health) was not clearly proven, with no statistically significant differences shown between the LDN-dosed group and the placebo group.

Research into LDN is also taking place for other conditions. In 2007, a 12-week trial into LDN’s effectiveness in the treatment of Crohn’s disease, conducted by Prof. J Smith and published in the American Journal of Gastroenterology, reported that 86 per cent of the 17 people enrolled in the trial showed a reduction in the activity of their condition as demonstrated by endoscopic examination.

In 2009, a study conducted by Dr Younger from Stamford University, and published in Pain Medicine, looked at LDN as a treatment for the pain associated with fibromyalgia. The study showed a thirty percent reduction in pain symptoms in people treated with LDN, compared to the placebo.

Add to Cart:

  • 992 Units in Stock
  • Manufactured by: Sun Pharmaceuticals

This product was added to our catalog on Thursday 30 July, 2015.

Customers who bought this product also purchased...

Your IP Address is:
Copyright © 2017 Serenity Pharmaceuticals. Powered by Zen Cart